Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-01E phase 2 sub-study of belzutifan in adolescents with selected solid tumors
MOH_2026-08-13_016990Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in pheochromocytoma, gastrointestinal stromal tumor (GIST), von Hippel–Lindau disease (VHL) and 1 more, sponsored by Merck & Co. Primary endpoint: Not specified. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomagastrointestinal stromal tumor (GIST)von Hippel–Lindau disease (VHL)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2026-08-13_016990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-13_016990.